- Home
- BCML vs INBX Comparison
BCML vs INBX Comparison
Compare BCML & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCML | INBX |
|---|---|---|
| Founded | 2004 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 348.1M | 430.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BCML | INBX |
|---|---|---|
| Price | $29.69 | $80.11 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $32.00 | N/A |
| AVG Volume (30 Days) | 22.6K | ★ 242.1K |
| Earning Date | 01-22-2026 | 11-14-2025 |
| Dividend Yield | ★ 3.95% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.10 | N/A |
| Revenue | ★ $94,896,000.00 | $1,400,000.00 |
| Revenue This Year | $0.51 | $563.00 |
| Revenue Next Year | $10.33 | N/A |
| P/E Ratio | $14.47 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.22 | $10.81 |
| 52 Week High | $33.15 | $94.57 |
Technical Indicators
Market Signals| Indicator | BCML | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 48.92 | 49.85 |
| Support Level | $29.41 | $76.22 |
| Resistance Level | $33.15 | $94.57 |
| Average True Range (ATR) | 1.08 | 7.21 |
| MACD | -0.23 | -1.31 |
| Stochastic Oscillator | 43.57 | 28.54 |
Price Performance
Historical ComparisonAbout BCML BayCom Corp
BayCom Corp is a bank holding company for United Business Bank. It provides a broad range of financial services to businesses and business owners as well as individuals through its full-service branches and loan production office. The company targets its services to small and medium-sized businesses, professional firms, real estate professionals, nonprofit businesses, labor unions, and related nonprofit entities and businesses and individual consumers. Its products and services include deposit products, personal accounts, loans, online banking, cash management, and business savings services.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.